Form 4 for ISRG Intuitive Surgical
Accepted 2021-07-26 00:00:00 ET · period of report 2021-07-23 · accession 0001035267-21-000127 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-26 | 2021-07-23 | ISRG | BARRATT CRAIG H | Dir | M - OptEx | $161.27 | +1,275 | 1,275 | New | +$205.6K |
| D | 2021-07-26 | 2021-07-23 | ISRG | BARRATT CRAIG H | Dir | S - Sale+OE | $967.20 | -1,275 | 0 | -100% | -$1.23M |
| D | 2021-07-26 | 2021-07-23 | ISRG | BARRATT CRAIG H | Dir | M - OptEx | $0.00 | -1,275 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-23 | M | A | 1,275 | $161.27 | 1,275 | D | — | — | |
| 2 | Common | Common Stock | 2021-07-23 | S | D | 1,275 | $967.20 | 0 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $963.28 to $975.41,inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-07-23 | M | D | 1,275 | $0.00 | 0 | D | $161.27 · — to 2023-04-25 | 1,275 Common Stock | (F3) Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company. |